| | | 债券代码：111015 债券简称：东亚转债 浙江东亚药业股份有限公司 关于不向下修正"东亚转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 自 2024 年 8 月 27 日至 2024 年 9 月 23 日，浙江东亚药业股份公司（以 下简称"公司"）股票在连续三十个交易日中已有十五个交易日收盘价格低于"东 亚转债"当期转股价格的 90%（即 18.25 元/股）的情形，满足《浙江东亚药业股 份有限公司向不特定对象发行可转换公司债券募集说明书》（以下简称"《募集 说明书》"）中规定的转股价格向下修正的条件。 自 2024 年 2 月 23 日至 2024 年 3 月 14 日，公司股票连续十五个交易日收 盘价格低于"东亚转债"当期转股价格的 90%（即 22.46 元/股）的情形，触发 "东亚转债"的转股价格修正条件。为支持公司长期稳健发展，优化公司资本结 构，维护投资者权益，自 2024 年 4 月 3 日起，"东亚转债"转股价格由 24.95 元 /股调整为 20.60 元/ ...

Company Overview - Zhejiang Dongya Pharmaceutical Co., Ltd. was established in 1998 and listed on the Shanghai Stock Exchange on November 25, 2020 [3] - The company specializes in the R&D, production, and sales of chemical raw materials and pharmaceutical intermediates, with a global sales network covering over 50 countries and regions [3] - The company has received multiple accolades, including "National High-tech Enterprise" and "Zhejiang Patent Demonstration Enterprise" [3] Business Strategy - The company aims to enhance its core competitiveness by expanding into generic drugs and innovative drugs while maintaining a focus on raw materials [4] - A long-term strategy is in place to develop a comprehensive health product provider, integrating specialty intermediates, high-end raw materials, and formulations [5] Financial Performance - For the first half of 2024, the company reported a revenue of CNY 648.23 million, a slight decrease of 3.85% year-on-year [4] - The net profit attributable to shareholders was CNY 32.47 million, down 40.54%, with a gross margin of 25.81%, an increase of 1.53% compared to the previous year [4] Market Demand and Trends - The demand for antibiotics remains strong due to factors such as flu outbreaks and the essential nature of antibiotics in healthcare [5] - Macroeconomic stability in China is driving an increase in disposable income and healthcare spending, contributing to a rigid growth in pharmaceutical consumption [5] Future Growth Points - The company has significant market space for its main products, driven by an aging population and increasing health awareness [8] - Ongoing investments in R&D are expected to yield new raw materials, with products like cefoperazone and luliconazole entering production [8] - The establishment of a formulation production base is anticipated to generate additional revenue and boost related raw material sales [8] Operational Insights - The company is currently developing a production base in Jiangxi, which is expected to enhance the variety and scale of production for intermediates and raw materials [6] - Management expenses have increased due to the establishment of new R&D centers and the expansion of production personnel [6] Investor Relations - The company has engaged in various investor relations activities, including analyst meetings and media interviews, to maintain transparency and communication with stakeholders [2]

Group 1: Company Growth Strategies - The company's future performance growth points include new product development, with ongoing investments in raw material drugs like Edaravone [3] - Capacity expansion is underway, with IPO fundraising projects completed in 2023 and production ramping up in 2024 [3] - The company is pursuing international certifications for raw materials to expand into high-end markets in Europe, the U.S., and Japan, as well as mid-to-low-end markets in Central Asia and the Middle East [3] - The completion of convertible bond fundraising projects is expected to significantly boost the growth of new formulation products [3] Group 2: Investment and Market Expansion - The establishment of a pharmaceutical investment fund aims to leverage raw material technology and capacity advantages to expand downstream formulation business [3] - In the first half of 2024, the company actively participated in international exhibitions and strengthened international registrations to enhance overseas market share [3] Group 3: Share Buyback and Financial Performance - As of July 31, 2024, the company completed its share buyback, acquiring 2.170103 million shares, representing 1.8911% of total share capital, with a total investment of 54.99217944 million yuan [3] Group 4: Production Capacity and Utilization - The company is progressing with capacity expansion, with high overall utilization rates and further growth potential as it expands into overseas markets [4] - The production facilities for the formulation segment are nearing completion, with ongoing expansion work for intermediates [4] Group 5: Future Development Strategy - The company plans to focus on raw materials while expanding into material chemistry and intermediates, as well as investing in generic drugs, improved new drugs, innovative drugs, and health products [4] - The goal is to achieve integrated development of specialty intermediates, high-end raw materials, and formulations, positioning the company as a comprehensive provider of health products [4] Group 6: Environmental Initiatives - The introduction of environmentally friendly biocatalytic processes aims to reduce costs and improve efficiency, with high acceptance rates among domestic and international customers [5]

Financial Performance - The company's operating revenue for the first half of 2024 was approximately CNY 648.23 million, a decrease of 3.85% compared to CNY 674.18 million in the same period last year[17]. - The net profit attributable to shareholders for the first half of 2024 was CNY 32.47 million, down 40.54% from CNY 54.61 million in the previous year[17][19]. - The basic earnings per share decreased by 39.58% to CNY 0.29 from CNY 0.48 in the same period last year[18]. - The company's net assets attributable to shareholders at the end of the reporting period were CNY 2.01 billion, a decrease of 0.42% from CNY 2.02 billion at the end of the previous year[17]. - The company reported a net cash flow from operating activities of CNY -122.65 million, indicating a significant cash outflow during the reporting period[17]. - The weighted average return on net assets decreased to 1.61%, down from 2.92% in the previous year, reflecting a decline of 1.31 percentage points[18]. - In the first half of 2024, the company achieved revenue of 648.23 million yuan, a decrease of 3.85% year-on-year, and a net profit of 32.47 million yuan, down 40.54% year-on-year[49]. - The company reported a total comprehensive income for the first half of 2024 of CNY 8,548,084.78, down from CNY 27,456,102.62 in the same period of 2023, indicating a decline of approximately 68.9%[142]. Research and Development - R&D investment in the first half of 2024 reached 52.80 million yuan, an increase of 70.16% year-on-year, accounting for 8.15% of total revenue[49]. - The company has established modern R&D centers in Shanghai and Hangzhou, and has received multiple certifications including CGMP and EDQM for its products[23]. - The company is focused on developing new products, including broad-spectrum antifungal agents and treatments for various infections[26]. - The company is actively transitioning from raw materials to formulations, aiming for integrated production to enhance product value and profitability[47]. - The company has obtained a total of 42 authorized patents, including 34 invention patents, as of June 30, 2024[45]. Market and Sales Strategy - The company has a global sales network covering over 50 countries and regions, with long-term partnerships established in Europe, Southeast Asia, and other areas[23]. - The company primarily utilizes direct sales in the domestic market, leveraging its scale and product quality to maintain customer relationships[30]. - The company has developed a dual sales model for international markets, combining direct sales and distributor partnerships to enhance market reach and efficiency[32]. - The company has formed stable partnerships with several high-market-share formulation enterprises, enhancing its competitive position in the market[41]. - The integration of APIs and formulations is becoming a key trend in the pharmaceutical manufacturing sector, supported by government policies promoting collaboration[38]. Financial Management and Governance - The company has established a profit distribution policy and shareholder dividend return plan, detailing the ratio, basis, conditions, and implementation procedures for dividends[103]. - The company is committed to enhancing investor returns and will publicly explain any failure to fulfill commitments at the shareholders' meeting[103]. - The company has implemented measures to ensure fair pricing in related transactions to protect the interests of the company and its shareholders[101]. - The company has a structured approach to managing related party transactions to avoid conflicts of interest[101]. - The company emphasizes the importance of independent directors and supervisory boards in safeguarding the interests of minority shareholders[103]. Environmental Management - The company has established a comprehensive environmental monitoring plan, with third-party testing confirming that all pollutant indicators meet discharge standards[90]. - The company has invested in waste treatment equipment to comply with environmental standards, but operational issues may still lead to penalties[64]. - The company has implemented an emergency response plan for environmental incidents, which has been filed with local environmental authorities[85]. - The company achieved a reduction of 53 tons in carbon dioxide equivalent emissions during the reporting period through various carbon reduction measures, including peak electricity usage management and solvent recovery[97]. - The company has received ISO14001 certification for its environmental management system, with re-certification planned for March 2024[96]. Risks and Challenges - There are no significant risks that materially affect the company's operations during the reporting period[5]. - The company faces risks related to industry policy changes, which could increase operational costs and impact performance if not adapted to timely[63]. - Environmental regulations are becoming stricter, potentially increasing the company's environmental management costs and affecting profitability[64]. - The company is exposed to risks from natural disasters, such as typhoons, which could disrupt normal operations[65]. - The company must renew key operational licenses periodically, and failure to do so could halt production and sales, impacting financial performance[63]. Shareholder and Capital Structure - The company repurchased 2,170,103 shares, accounting for 1.8911% of the total share capital, with a total repurchase amount of 54,992,179.00 RMB, reflecting a commitment to long-term value and employee incentives[51]. - The company’s major shareholders have committed to not interfere with the company's management activities and to comply with relevant regulations[106]. - The company has pledged to adhere to the latest regulations from the China Securities Regulatory Commission regarding compensation measures[106]. - The controlling shareholders have pledged not to sell their shares through secondary markets or bulk transactions for the next 12 months, reinforcing investor confidence[109]. - The company has a total of 9,554 common shareholders as of the end of the reporting period[122]. Compliance and Legal Matters - There are no significant lawsuits or arbitration matters reported during the reporting period, indicating a stable legal environment for the company[110]. - The company has not engaged in any major related party transactions during the reporting period, maintaining transparency in its financial dealings[111]. - There are no non-operational fund occupations by controlling shareholders or related parties, ensuring proper use of company funds[110]. - The company has not reported any violations or penalties against its directors, supervisors, or senior management, reflecting good governance practices[110]. - The company has not disclosed any major contracts or their execution status, suggesting a focus on operational efficiency[111].

浙江东亚药业股份有限公司 关于聘任董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2024-070 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 周剑波先生具有良好的职业道德和个人品质，具备履行职责所必须的专业知 识和工作经验。周剑波先生已取得上海证券交易所颁发的科创板上市公司《董事 会秘书资格证明》，暂未完成上海证券交易所主板上市公司董事会秘书任前培训， 其承诺将参加最近一期上海证券交易所主板上市公司董事会秘书任职资格培训。 浙江东亚药业股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日召开了 第三届董事会第二十八次会议，审议通过了《关于聘任公司董事会秘书的议案》， 现将有关情况公告如下： 截至本公告日，周剑波先生未持有公司股份，与公司控股股东、实际控制人 以及其他董事、监事、高级管理人员和持股 5%以上公司股东不存在关联关系, 亦不存在被中国证监会、证券交易所或其他有 ...

二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2024-069 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 第三届董事会第二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第三届董事会第二十八次会议 于 2024 年 8 月 29 日（星期四）以现场结合通讯的方式召开。本次会议通知于 2024 年 8 月 19 日以邮件的方式发出。本次会议应出席董事 7 人，实际出席董事 7 人。 会议由公司董事长池正明先生主持，监事、高管列席会议。本次会议的召集、 召开符合《中华人民共和国公司法》等法律、法规和《公司章程》的有关规定。 （三）审议通过《关于 2024 年半年度募集资金存放与实际使用情况的专项报告 的议案》 （一）审议通过《关于聘任董事会秘书的议案》 本议案已经公司董事会 ...

一、可转换公司债券募集资金基本情况 （一）实际可转换公司债券募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意浙江东亚药业股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2023〕1165 号）核准，同 意公司向不特定对象发行可转换公司债券注册申请。截止 2023 年 7 月 12 日止， 公司向不特定对象发行可转换公司债券人民币普通股（A 股）股票为人民币 69,000.00 万元（690,000 手，6,900,000 张），每张面值为人民币 100.00 元，按票 面金额发行，债券期限为 6 年。公司申请发行的可转换公司债券募集资金总额为 人民币 69,000.00 万元，扣除承销费及其他发行费用人民币（不含增值税）981.56 万元后，实际募集资金净额为人民币 68,018.44 万元。本次发行募集资金已于 2023 年 7 月 12 日全部到账，并经中汇会计师事务所（特殊普通合伙）审验，于 2023 年 7 月 12 日出具了《债券募集资金到位情况验证报告》（中汇会验[2023]8458 号）。 | 证券代码：605177 | 证券简称：东亚药业 公告编号：2024 ...

浙江东亚药业股份有限公司 | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2024-067 | | --- | --- | --- | | 债券代码：111015 | 转债简称：东亚转债 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江东亚药业股份有限公司（以下简称"公司"）近日收到东兴证券股份有 限公司（以下简称"东兴证券"）《关于浙江东亚药业股份有限公司持续督导更 换保荐代表人的情况说明》。 2024 年 8 月 26 日 1 关于变更持续督导保荐代表人的公告 东兴证券作为公司向不特定对象发行可转换公司债券的保荐机构，原已委派 了保荐代表人阮瀛波先生和曾文倩女士履行持续督导职责，持续督导期自 2023 年 7 月至 2024 年 12 月。因阮瀛波先生、曾文倩女士工作变动，为保证持续督导 工作的有序进行，现东兴证券委派张昱先生和陆丹彦女士（简历附后）担任公司 持续督导保荐代表人，继续履行持续督导职责。 本次保荐代表人更换后，公司持续督导保荐代表人为张昱先生和陆丹彦女士， 持续督导期至中国证券监 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2024-066 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于回购股份期限届满暨回购实施结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。。 重要内容提示： | 回购方案首次披露日 | 2023/8/2 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2023 年 8 月 日~2024 年 7 月 | 1 | 31 | 日 | | 预计回购金额 | 万元 5,000 万元~10,000 | | | | | 回购价格上限 | 38.86 元/股 | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 实际回购股数 | 万股 217.0103 | | | | | 实际回购股数占总股本比例 | 1. ...

浙江东亚药业股份有限公司 关于合作设立医药投资基金并共同发起设立 医药开发公司的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资的概述 浙江东亚药业股份有限公司（以下简称"公司"或"东亚药业"）系一家从 事原料药及医药中间体的研发、生产与销售的上市公司，利用原料药技术与产能 优势，拓展下游制剂业务，实现向原料药+制剂一体化发展转型。 公司于 2024 年 5 月 20 日召开第三届董事会第二十七次会议、第三届监事会 第二十五次会议，审议通过《关于拟合作设立医药投资基金并共同发起设立医药 开发公司的议案》。公司拟使用自有资金与杭州嘉富天成股权投资管理有限公司、 三门县金融投资有限责任公司、台州市北部湾区经济开发集团有限公司、台州市 海盛产业投资有限公司共同出资设立台州嘉富泽亚股权投资合伙企业（有限合伙） （以下简称"合伙企业"）；后续与该合伙企业共同投资设立一家专业从事制剂 开发的三门善祥医药研究有限公司（暂定名，最终名称以工商核准登记为准，以 下简称"药证公司"），由药证公司自主研发或委托 CRO 机构开 ...